Publications by authors named "Yi-Ming Jia"

Article Synopsis
  • This research investigates the connection between sleep disorders (SD) and major depressive disorder (MDD), focusing on how SD impacts cognitive function.
  • The study included 372 MDD patients and 457 healthy controls, finding that MDD patients are 38.88 times more likely to have a sleep disorder compared to healthy individuals.
  • Results suggest that sleep disorders contribute to greater impairment in visuospatial and constructional abilities among MDD patients, and improving sleep quality and addressing depression can help mitigate these cognitive deficits.
View Article and Find Full Text PDF

Underlying pivotal pathways were identified to reveal potential key genes correlated with postmenopausal osteoporosis (PMOP). The pathways were enriched by Kyoto Encyclopedia of Genes and Genomes (KEGG) with genes intersection greater than 5 based on gene expression profile data, and the acquired pathways were then transformed to Markov chain (MC). Gibbs sampling was conducted to obtain a new MC.

View Article and Find Full Text PDF

The reactions of Ni with propionaldehyde in the gas phase have been systematically investigated using density functional theory at the B3LYP/def2-TZVP level. The decomposition reaction mechanism has been identified. Our calculations indicated that Ni can assist decomposition of propionaldehyde to form NiCO and CH through two types of reaction channel: C-C bond activation and C-H bond activation.

View Article and Find Full Text PDF

Magnesium isoglycyrrhizinate (MI) has been complementarily used for restoring the hepatic impairments caused by taxol plus platinum based chemotherapies in China. Due to the hepatic dependence of paclitaxel elimination, this pilot clinical study aimed to investigate the influence of MI on the pharmacokinetics of paclitaxel in epithelial ovarian cancer patients. During the standard chemotherapy of intravenous paclitaxel (125 mg/m(2) infused over a 3-h period) and intraperitoneal cisplatin (60 mg/m(2)) for patients with FIGO stage II epithelial ovarian cancer, 9 each of total 18 patients were respectively treated with intravenous MI (100 mg) or vehicle control for 4 days.

View Article and Find Full Text PDF